{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma+Grade+2&page=18",
    "query": {
      "condition": "Follicular Lymphoma Grade 2",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 794,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma+Grade+2&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma+Grade+2&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T12:49:14.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05064319",
      "title": "Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Cannabis Use",
        "Schizoaffective Disorder, Bipolar Type",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Cannabis Use Disorder, Mild",
        "Cannabis Use Disorder, Moderate",
        "Cannabis Use Disorder, Severe"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2022-02-24",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064319"
    },
    {
      "nct_id": "NCT00005950",
      "title": "506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angioimmunoblastic T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "nelarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2000-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005950"
    },
    {
      "nct_id": "NCT04345718",
      "title": "EXHIT ENTRE Comparative Effectiveness Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Substance Use Disorder",
        "Opioid Use Disorder, Moderate",
        "Opioid Use Disorder, Severe"
      ],
      "interventions": [
        {
          "name": "Extended Release Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Treatment as Usual",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gavin Bart",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2021-08-09",
      "completion_date": "2025-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04345718"
    },
    {
      "nct_id": "NCT05111509",
      "title": "A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor Grade 2",
        "Neuroendocrine Tumor Grade 1"
      ],
      "interventions": [
        {
          "name": "[203Pb]VMT-α-NET",
          "type": "DRUG"
        },
        {
          "name": "SPECT/CT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Yusuf Menda",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-08-22",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05111509"
    },
    {
      "nct_id": "NCT00005967",
      "title": "Tipifarnib in Treating Patients With Advanced Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2000-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005967"
    },
    {
      "nct_id": "NCT00625729",
      "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic natural killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00625729"
    },
    {
      "nct_id": "NCT01254578",
      "title": "Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1",
        "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A",
        "Adult Acute Promyelocytic Leukemia With PML-RARA",
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Adult Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Alkylating Agent-Related Acute Myeloid Leukemia",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Hepatosplenic T-Cell Lymphoma",
        "Intraocular Lymphoma",
        "Lymphomatous Involvement of Non-Cutaneous Extranodal Site",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Post-Transplant Lymphoproliferative Disorder",
        "Primary Cutaneous B-Cell Non-Hodgkin Lymphoma",
        "Prolymphocytic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Richter Syndrome",
        "Small Intestinal Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "T-Cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2010-11-24",
      "completion_date": "2012-11-09",
      "has_results": false,
      "last_update_posted_date": "2017-09-25",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01254578"
    },
    {
      "nct_id": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "agatolimod sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-03",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040950"
    },
    {
      "nct_id": "NCT06860594",
      "title": "Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma, IDH-Mutant, Grade 2",
        "Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant",
        "Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 3",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Triapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 43,
      "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 34 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06860594"
    },
    {
      "nct_id": "NCT00996359",
      "title": "Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Irradiated haploidentical allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-10",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-15T12:49:14.855Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996359"
    }
  ]
}